Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of CC-10004 in moderate-to-severe plaque psoriasis
2006-000057-22Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of apremilast in psoriasis (3 arms), sponsored by Celgene Corporation. Primary endpoint: PASI-75 response at Week 12. Started Mar 2006; status: completed.
02
Drugs
apremilast
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2006-000057-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000057-22.